Discussion
A new biotechnology company called Rinascera Therapeutics has launched to develop therapies for people with epidermolysis bullosa and other rare genetic skin diseases. The company is working to advance two treatment candidates. RIN-002 is being developed for dystrophic epidermolysis bullosa (DEB), while RIN-001 is being developed for another…